Skip to main navigation Skip to search Skip to main content

Natural products-based antiangiogenic agents: New frontiers in cancer therapy

  • Tiago Azevedo
  • , Tiago Ferreira
  • , Sheila I. Peña-Corona
  • , Hernán Cortes
  • , Rita Silva-Reis
  • , Rui M.Gil da Costa
  • , Ana I. Faustino-Rocha
  • , Paula A. Oliveira
  • , Daniela Calina
  • , Susana M. Cardoso
  • , Dietrich Büsselberg
  • , Gerardo Leyva-Gómez
  • , Javad Sharifi-Rad
  • , William C. Cho
  • Universidade de Trás-os-Montes e Alto Douro
  • Universidad Nacional Autónoma de México
  • Instituto Nacional de Rehabilitación
  • University of Aveiro
  • Instituto Português de Oncologia do Porto Francisco Gentil E.P.E.
  • University of Porto
  • Universidade Federal do Maranhão
  • University of Évora
  • Craiova University of Medicine and Pharmacy
  • Qatar Foundation
  • Queen Elizabeth Hospital Hong Kong

Research output: Contribution to journal › Article › peer-review

23 Scopus citations

Abstract

Angiogenesis, vital for tumor growth and metastasis, is a promising target in cancer therapy. Natural compounds offer potential as antiangiogenic agents with reduced toxicity. This review provides a comprehensive overview of natural product-based antiangiogenic therapies, focusing on molecular mechanisms and therapeutic potential. A systematic search identified relevant articles from 2019 to 2023. Various natural compounds, including polyphenols, terpenes, alkaloids, cannabinoids, omega-3 fatty acids, polysaccharides, proteins, and carotenoids, were investigated for their antiangiogenic properties. Challenges such as dose standardization, routes of administration, and potential side effects remain. Further studies, including in-depth animal models and human epidemiological studies, must elucidate clinical efficacy and safety. Synergistic effects with current antiangiogenic therapies, such as bevacizumab and tyrosine kinase inhibitors, should be explored. Additionally, the potential hormone-dependent effects of compounds like genistein highlight the need for safety evaluation. In conclusion, natural products hold promise as adjunctive therapies to conventional antineoplastic drugs in modulating angiogenesis in cancer. However, robust clinical trials are needed to validate preclinical findings and ensure safety and efficacy.

Original languageEnglish
Pages (from-to)2423-2466
Number of pages44
JournalFood Frontiers
Volume5
Issue number6
DOIs
StatePublished - Nov 2024

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • angiogenesis
  • antiangiogenic therapy
  • cancer treatment
  • molecular mechanisms
  • natural compounds

Fingerprint

Dive into the research topics of 'Natural products-based antiangiogenic agents: New frontiers in cancer therapy'. Together they form a unique fingerprint.

Cite this